IDT Biologika
Dedicated to Contract Development and Manufacturing of
Viral Vaccines, Viral Vectors and Biologics

IDT Biologika specializes in the contract development and manufacturing of Viral Vaccines, Gene and Immunotherapeutics as well as sterile liquids and lyophilized Biologics. We help biopharmaceutical and biotech companies as well as the US government as part of research consortia with the challenging and complex process of translating viral vaccines and biopharmaceuticals from the research lab through clinical development to large-scale commercial manufacturing including drug substance production, fill & finish, packaging and analytics. IDT Biologika provides fully integrated services for GMP compliant end-to-end services in BSL2 facilities meeting EMA, FDA and ANVISA standards.

We strive for strong, trusting and enduring customer partnerships. Our almost 100 year tradition in manufacturing vaccines and biopharmaceuticals motivates and obligates us to advance our clients’ products to prevent and treat diseases that impact the health of people worldwide.


Our Awards

CMO Leadership Award 2021


CMO Leadership Award 2021


PharmaTech Outlook


Focus Innovation Award


@IDT Biologika

Friday, 11. June 2021

Our story continues. See here the next piece of the exciting 100-year-history of #IDT Biologika. We feature 3… more info

Wednesday, 19. May 2021

We are proud to announce that we are now a member of #VaccinesEurope – a voice for the vaccines industry in Europe.… more info

Wednesday, 5. May 2021

Running well! Our #IDT running team is taking part in the 10-week running challenge organized by the state of… more info

Wednesday, 21. April 2021

The next article on our 100 year history is now online. We invite you to learn more about research, #development an… more info

Thursday, 8. April 2021

IDT Biologika has laid the foundation stone for further capacities for the manufacture of active ingredients for va… more info

Tuesday, 30. March 2021 more info

Tuesday, 23. March 2021 more info

Monday, 15. March 2021

IDT Biologika is now using capacities at its Dessau site previously reserved for Takeda Pharmaceutical Company's de… more info

Thursday, 4. March 2021

As a contract manufacturer of vaccines for the worldwide protection of people against infectious diseases, we act e… more info

Federal Minister of Health Jens Spahn and Prime Minister Reiner Haseloff visit IDT Biologika

Monday, 19. April 2021

Dessau-based company to now fill AstraZeneca COVID-19 vaccine - Merz Pharma is foregoing capacities at short notice more info

IDT Biologika lays foundations for new multifunctional vaccine production building

Thursday, 8. April 2021

Overall, a total of 100 million euros are currently being invested in the site... more info

IDT Biologika and Takeda support production of the Johnson & Johnson single-shot COVID-19 vaccine

Monday, 15. March 2021

Takeda provides booked capacity at the IDT site in Dessau more info

Start of second study phase of vector vaccine against COVID-19 postponed

Monday, 11. January 2021

Initial data for corona vaccine indicate good tolerability but weak immune response more info

Federal Minister of Health visits IDT Biologika

Tuesday, 24. November 2020

5 million vaccine doses against COVID-19 more info